Roche’s Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson’s disease PADOVA study showed numerical delay in motor progression and...
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution Roche launches its cobas® Mass Spec solution, bringing mass spectrometry to the routine clinical labClinical...
Roche’s Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness Vabysmo PFS is the first and only prefilled syringe containing a bispecific...
Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities The new cobas 6800/8800 systems 2.0 enhances throughput, run...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma Long-term data confirm fixed-duration...
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash Basel, 9...
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma Exploratory long-term follow-up analysis of the phase III POLARIX...
FDA accepts supplemental Biologics License Application for Roche’s Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma Application is based on data from the...
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and...
Roche reports update on Phase III SKYSCRAPER-01 study results Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 229.2 | 229.2 | 229.2 | 937 | 229.2 | DE |
4 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5535 | 229.2 | DE |
12 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4792 | 229.2 | DE |
26 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4445 | 229.2 | DE |
52 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5209 | 229.2 | DE |
156 | 0 | 0 | 229.2 | 229.2 | 229.2 | 6094 | 229.2 | DE |
260 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4941 | 229.2 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約